Obesity and depression: pathogenetic role of sleep and wakefulness regulation, motoric activity level and neurochemical aspects

Obesity and depression: pathogenetic role of sleep and wakefulness regulation, motoric activity level and neurochemical aspects - OBDEP

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00004190

Enrollment

300

Registered

2012-06-21

Start date

2011-02-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E66 F32

Interventions

Group 1: obesity without depression: no standardized treatment

diagnostics: electroencephalography EEG, accelerometry, blood analysis, questionnaires Group 2: obesity with depression: no standardized treatment

diagnostics: electroencephalography EEG, accelerometry, blood analysis, questionnaires Group 3: depression without obesity: no standardized treatment

diagnostics: electroencephalography EEG, accelerometry, blood analysis, questionnaires Group 4: lean, healthy controls: no standardized treatment

diagnostics: electroencephalography EEG, accelerometry, blood analysis, questionnaires

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Arm 1: BMI > 35 and no history of depression Arm 2: BMI > 35 and current depressive episode Arm 3: BMI < 30 and current depressive episode Arm 4: BMI < 30 and no history of depression

Exclusion criteria

Exclusion criteria: other DSM-IV Axis 1 disorders use of illegal drugs abuse of alcohol within the past 6 months a history of head injury with loss of consciousness exceeding one hour major somatic disorders

Design outcomes

Primary

Measure	Time frame
Vigilance regulation is the primary outcome. It will be assessed using EEG and vigilance stages will be classified using a Wakefulness-Assessment-Tool. There will be a baseline and a follow-up assessment after 6 months for all of the 300 subjects.	—

Secondary

Measure	Time frame
Secondary outcomes are: Hormone, neuropeptid- und cytokine levels will be assessed using blood samples. Motor activity will be assessed and analyzed using accelometry (Sensewear devices and software). Affektive und behavioural parameters will be assessed and analyzed using questionnaires (Beck-Depression-Inventory II, Hamilton Depression Rating Scale) Secondary outcomes will be assessed at baseline and at follow-up after 6 months.	—

Measure

Time frame

Secondary outcomes are: Hormone, neuropeptid- und cytokine levels will be assessed using blood samples. Motor activity will be assessed and analyzed using accelometry (Sensewear devices and software). Affektive und behavioural parameters will be assessed and analyzed using questionnaires (Beck-Depression-Inventory II, Hamilton Depression Rating Scale) Secondary outcomes will be assessed at baseline and at follow-up after 6 months.

—

Countries

Germany

Contacts

Public ContactTobias Chittka

IFB AdipositasErkrankungen

tobias.chittka@medizin.uni-leipzig.de0341 9724498

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026